Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Essex Bio-Technology Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Haizhou Fang

Geschäftsführender

HK$1.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	97.5%
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	0.9%
Durchschnittliche Amtszeit des Managements	23.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.8yrs

Jüngste Management Updates

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Recent updates

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Haizhou Fang im Vergleich zu den Einnahmen von Essex Bio-Technology verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	HK$2m	HK$2m	HK$275m
Sep 30 2023	n/a	n/a	HK$266m
Jun 30 2023	n/a	n/a	HK$256m
Mar 31 2023	n/a	n/a	HK$241m
Dec 31 2022	HK$2m	HK$2m	HK$225m
Sep 30 2022	n/a	n/a	HK$274m
Jun 30 2022	n/a	n/a	HK$323m
Mar 31 2022	n/a	n/a	HK$334m
Dec 31 2021	HK$2m	HK$2m	HK$346m
Sep 30 2021	n/a	n/a	HK$339m
Jun 30 2021	n/a	n/a	HK$332m
Mar 31 2021	n/a	n/a	HK$275m
Dec 31 2020	HK$2m	HK$2m	HK$219m
Sep 30 2020	n/a	n/a	HK$221m
Jun 30 2020	n/a	n/a	HK$222m
Mar 31 2020	n/a	n/a	HK$262m
Dec 31 2019	HK$2m	HK$737k	HK$303m
Sep 30 2019	n/a	n/a	HK$282m
Jun 30 2019	n/a	n/a	HK$262m
Mar 31 2019	n/a	n/a	HK$246m
Dec 31 2018	HK$2m	HK$766k	HK$231m
Sep 30 2018	n/a	n/a	HK$210m
Jun 30 2018	n/a	n/a	HK$189m
Mar 31 2018	n/a	n/a	HK$178m
Dec 31 2017	HK$2m	HK$721k	HK$167m

Vergütung im Vergleich zum Markt: HaizhouDie Gesamtvergütung ($USD223.29K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD349.42K).

Entschädigung vs. Einkommen: HaizhouDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Haizhou Fang (58 yo)

no data

Amtszeit

HK$1,744,587

Vergütung

Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mia Je Ngiam	Founder & Chairman	no data	HK$3.23m	52.74% HK$ 772.2m
Haizhou Fang	MD & Executive Director	no data	HK$1.74m	0.92% HK$ 13.5m
Hian Leng Ngiam	Executive Director & Deputy MD	no data	HK$1.80m	0.36% HK$ 5.3m
Lai Man Yau	Executive Director & Company Secretary	23.4yrs	HK$755.60k	0.0081% HK$ 118.8k
Qi Xue	Group Chief Scientific Officer	6.2yrs	keine Daten	keine Daten

23.4yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 1061 ist erfahren und erfahren (durchschnittliche Amtszeit: 23.3 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mia Je Ngiam	Founder & Chairman	no data	HK$3.23m	52.74% HK$ 772.2m
Haizhou Fang	MD & Executive Director	no data	HK$1.74m	0.92% HK$ 13.5m
Hian Leng Ngiam	Executive Director & Deputy MD	3.8yrs	HK$1.80m	0.36% HK$ 5.3m
Lai Man Yau	Executive Director & Company Secretary	3.8yrs	HK$755.60k	0.0081% HK$ 118.8k
Chi Ying Fung	Independent Non Executive Director	23yrs	HK$250.00k	keine Daten
Mee Mooi Yeow	Independent Non Executive Director	19.8yrs	HK$220.00k	keine Daten
Man Sing Yan	Independent Non-Executive Director	less than a year	HK$128.33k	keine Daten

3.8yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: 1061Die Vorstandsmitglieder gelten als erfahren (3.7 Jahre durchschnittliche Amtszeit).

Essex Bio-Technology Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Recent updates

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Investor sentiment improved over the past week

New 90-day high: HK$4.40

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

New 90-day low: HK$3.74

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

New 90-day low: HK$3.96

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Executive Director & Company Secretary recently bought HK$193k worth of stock

New 90-day low: HK$3.99

New 90-day low: HK$4.43